Combining-Topiramate-Valproic acid
From Psychiatrienet
| ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
Adding valproic acid to topiramate.
General information- Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
- Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
- This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. Dose adaptation will be recommended for this combination.
Start valproic acid- Start valproic acid according to the general dosing advice.
- Pharmacologic response to the drugs should be monitored more closely following addition or withdrawal of one or the other drug. Dose adjustments may be required if an interaction is suspected.
Cave- Topiramate plasma levels are increased by about 15% by valproate, which could be important if valproate is withdrawn. [4]
- ↑ 1.0 1.1 1.2 Farmacotherapeutisch Kompas - topiramaat (dutch)
Cite error: Invalid
<ref>tag; name "ftk" defined multiple times with different content - ↑ Farmacotherapeutisch Kompas; Toxicologie (dutch)
- ↑ KNMP; Informatorium Medicamentorum 2023; Monografie "valproaat" (Dutch)
- ↑ Bazire S, Psychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
